全国同城凤凰楼信息茶楼_51pcmc品茶2024官网_全国兼职凤凰楼信息

教育经历
2009.09-2013.06，本科，中国药科大学，药物制剂专业。
2013.09-2016.06，硕士，中国药科大学，药剂学专业，导师：张灿教授。
2016.09-2019.12，博士，中国药科大学，药剂学专业，导师：莫然教授。
工作经历
2020.01-2022.10，中国药科大学药物科学研究院，博士后。
2022.10-至今，中科中山药物创新研究院，副研究员/青年课题组长。

1. 靶向递药与智能释药体系的研究。

2. 免疫调节型药物递送系统的研究。

3. 高端药物制剂与创新剂型的开发。

从事高端药物制剂以及药用功能材料的研究，致力于设计高效的药物递送系统，并探索其在重大疾病治疗中的相关应用与具体机制，重点围绕克服恶性肿瘤的耐药构建了一系列智能化治疗策略。以第一作者身份在Nature Nanotechnology、Nano Letters等国际高水平期刊上发表多篇研究论文，平均影响因子达18，主持国家自然科学基金青年科学基金、中国博士后科学基金特别资助等5项科研项目，申请2项发明专利。

(1) Shiyang Shen^#; Teng Li^#; Jinyi Fan; Quanlin Shao; He Dong; Xiao Xu; Ran Mo*. Lipid-polymer hybrid nanoparticle with cell-distinct drug release for combination cancer treatment. Acta Pharmaceutica Sinica B, 2022, In press.

(2) Shiyang Shen^#; Shiqi Lin^#; Yuying Chen; Ying Zhang; Yingjiao He; Xiao Xu; Yang Feng; Yougong Lu; Ran Mo*. Combating cancer stem-like cell-derived resistance to anticancer protein by liposome-mediated acclimatization strategy. Nano Letters, 2022, 22(6), 2419-2428.

(3) Shiyang Shen; Xiao Xu; Shiqi Lin; Ying Zhang; Huayu Liu; Can Zhang; Ran Mo*. A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells. Nature Nanotechnology, 2021, 16(1), 104-113. (WOS高被引论文)

(4) Shiyang Shen^#; Li Zhang^#; Mengru Li; Zhizi Feng; Huixia Li; Xiao Xu; Shiqi Lin; Ping Li; Can Zhang; Xiaojun Xu*; Ran Mo*. Collaborative assembly-mediated siRNA delivery for relieving inflammation-induced insulin resistance. Nano Research, 2020, 13(11), 2958-2966.

(5) Meng Liu^#; Shiyang Shen^#; Di Wen; Mengru Li; Teng Li; Xiaojie Chen; Zhen Gu*; Ran Mo*. Hierarchical nanoassemblies-assisted combinational delivery of cytotoxic protein and antibiotic for cancer treatment. Nano Letters, 2018, 18(4), 2294-2303.

(6) Shiyang Shen; Meng Liu; Teng Li; Shiqi Lin; Ran Mo*. Recent progress in nanomedicine-based combination cancer therapy using a site-specific co-delivery strategy. Biomaterials Science, 2017, 5(8), 1367-1381. (内封面论文)

(7) Xiao Xu; Xuechao Huang; Ying Zhang; Shiyang Shen; Zhizi Feng; He Dong; Can Zhang; Ran Mo*. Self-regulated hirudin delivery for anticoagulant therapy. Science Advances, 2020, 6(41), eabc0382.

(8) Haojie Wang^#; Xiao Xu^#; Xin Guan; Shiyang Shen; Xuechao Huang; Guoyin Kai; Shunyi Zhao; Wenchen Ruan; Luyong Zhang; Tao Pang*; Ran Mo*. Liposomal 9-aminoacridine for treatment of ischemic stroke: From drug discovery to drug delivery. Nano Letters, 2020, 20(3), 1542-1551.

(9) Xiao Xu^#; Teng Li^#; Shiyang Shen; Jinqiang Wang; Peter Abdou; Zhen Gu*; Ran Mo*. Advances in engineering cells for cancer immunotherapy. Theranostics, 2019, 9(25), 7889-7905.

(10) Tianyue Jiang; Shiyang Shen; Tong Wang; Mengru Li; Bingfang He*; Ran Mo*. A substrate-selective enzyme-catalysis assembly strategy for oligopeptide hydrogel-assisted combinatorial protein delivery. Nano Letters, 2017, 17(12), 7447-7454.

(11) Jingwei Xue; Zekai Zhao; Lei Zhang; Lingjing Xue; Shiyang Shen; Yajing Wen; Zhuoyuan Wei; Lu Wang; Lingyi Kong; Hongbin Sun; Qineng Ping; Ran Mo*; Can Zhang*. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nature Nanotechnology, 2017, 12(7), 692-700.